Zenosense, Inc.’s (ZENO) Heart Attack Testing Te
Post# of 53
(Total Views: 128)
Posted On: 09/24/2018 6:10:54 PM
Zenosense, Inc.’s (ZENO) Heart Attack Testing Technology Development Continues to Advance Hopes of Portable Point of Care Device
- Company’s MIDS Cardiac device aims to help ER personnel perform quick, high-sensitivity analysis of heart events
- MIDS device’s handheld portability is being developed to allow quick-response resource to minimally trained ambulance personnel
- Final device could ultimately help save patients, health insurers from unnecessary evaluation expenses
Heart disease remains the leading cause of death in men and women within the United States (http://nnw.fm/zVc6d), accounting for one out of every four deaths, and, as such, is fertile ground for research that is published regularly in professional periodicals such as the Journal of the American Heart Association (http://nnw.fm/h6wiZ). The ailment is also the inspiration for a variety of business enterprises aiming to help the public reduce heart disease risks, and among those companies is health care technology company Zenosense, Inc. (OTCQB: ZENO), a co-owner of the United Kingdom’s MIDS Medical Limited (MML) and its innovative handheld MIDS technology, as implemented in the ongoing development of its MIDS Cardiac device.
MIDS Cardiac aims is to deliver true laboratory accuracy, performing high-sensitivity troponin tests in the emergency room or out in the field to better identify if a patient with chest pain or shortness of breath is experiencing a myocardial infarction. Troponin is a heart protein generally searched for by emergency room physicians as a quick indicator if damaged cardiac cells have entered the blood stream, and new age high-sensitivity troponin tests are delivering critical information to doctors more rapidly than before.
The majority of patients presenting themselves with chest pain or shortness of breath are ultimately found to not be experiencing acute heart attacks, but the critical concern associated with their symptoms can lead to unnecessary hospital admissions and tests that increase the medical expenses borne largely by patients and their insurance providers.
Best-practice diagnostics not only minimize the risk of unnecessary medical expenses; they pave the way for patients to receive the appropriate medical treatment for their conditions. The in-development MIDS device has particular importance in establishing the proper treatment of such events.
“Chest discomfort is one of the most commonly-encountered complaints in outpatient medicine, and represents a major diagnostic challenge as patients often present with a broad range of non-specific symptoms or signs,” Dr. James Januzzi Jr. of Massachusetts General Hospital wrote in a report on one heart diagnostics study (http://nnw.fm/K1SgK).
Zenosense is developing the MIDS Cardiac device to help ER doctors rapidly conduct high-sensitivity troponin tests and also to make the technology portably available to ambulance first responders as they are treating patients in the first moments of an incident at a distance from the hospital. MIDS Cardiac aims to provide laboratory standard results within three minutes and additional cardiac biomarker testing within eight minutes utilizing a single pinprick of blood.
High-sensitivity troponin testing has been in clinical use in other parts of the world, including Europe, Canada and Australia, for over seven years, but the United States only approved the first such analyses last year (http://nnw.fm/jc2L0). As a result, no point of care tools are available to conduct true high-sensitivity testing, making the need for portable devices such as the MIDS product apparent. The technology is being developed to enable automated operation of the final device, suitable for use by minimally trained personnel, even in an ambulatory setting.
In July, the company posted quantitative testing results indicating that the MIDS technology had successfully detected a number of assay beads approximately four times lower than the maximum threshold required as suitable for a high-sensitivity troponin assay.
“The results of this second round of testing are quite extraordinary, as magnetic detection at this level for this application is unheard of,” Managing Director and Chief Scientific Officer Dr. Nasser Djennati stated in a news release (http://nnw.fm/DhGi7). “We can now move forward and apply the MIDS detection to established assay techniques used in conventional analyzers as we seek to deliver state-of-the-art laboratory standard, high sensitivity cardiac troponin testing at the Point of Care.”
Planning is now underway for the next key phase of development to test microfluidic detection on the revised electronics platform and to embody a high sensitivity assay on a test strip.
For more information, visit the company’s website at www.Zenosense.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Company’s MIDS Cardiac device aims to help ER personnel perform quick, high-sensitivity analysis of heart events
- MIDS device’s handheld portability is being developed to allow quick-response resource to minimally trained ambulance personnel
- Final device could ultimately help save patients, health insurers from unnecessary evaluation expenses
Heart disease remains the leading cause of death in men and women within the United States (http://nnw.fm/zVc6d), accounting for one out of every four deaths, and, as such, is fertile ground for research that is published regularly in professional periodicals such as the Journal of the American Heart Association (http://nnw.fm/h6wiZ). The ailment is also the inspiration for a variety of business enterprises aiming to help the public reduce heart disease risks, and among those companies is health care technology company Zenosense, Inc. (OTCQB: ZENO), a co-owner of the United Kingdom’s MIDS Medical Limited (MML) and its innovative handheld MIDS technology, as implemented in the ongoing development of its MIDS Cardiac device.
MIDS Cardiac aims is to deliver true laboratory accuracy, performing high-sensitivity troponin tests in the emergency room or out in the field to better identify if a patient with chest pain or shortness of breath is experiencing a myocardial infarction. Troponin is a heart protein generally searched for by emergency room physicians as a quick indicator if damaged cardiac cells have entered the blood stream, and new age high-sensitivity troponin tests are delivering critical information to doctors more rapidly than before.
The majority of patients presenting themselves with chest pain or shortness of breath are ultimately found to not be experiencing acute heart attacks, but the critical concern associated with their symptoms can lead to unnecessary hospital admissions and tests that increase the medical expenses borne largely by patients and their insurance providers.
Best-practice diagnostics not only minimize the risk of unnecessary medical expenses; they pave the way for patients to receive the appropriate medical treatment for their conditions. The in-development MIDS device has particular importance in establishing the proper treatment of such events.
“Chest discomfort is one of the most commonly-encountered complaints in outpatient medicine, and represents a major diagnostic challenge as patients often present with a broad range of non-specific symptoms or signs,” Dr. James Januzzi Jr. of Massachusetts General Hospital wrote in a report on one heart diagnostics study (http://nnw.fm/K1SgK).
Zenosense is developing the MIDS Cardiac device to help ER doctors rapidly conduct high-sensitivity troponin tests and also to make the technology portably available to ambulance first responders as they are treating patients in the first moments of an incident at a distance from the hospital. MIDS Cardiac aims to provide laboratory standard results within three minutes and additional cardiac biomarker testing within eight minutes utilizing a single pinprick of blood.
High-sensitivity troponin testing has been in clinical use in other parts of the world, including Europe, Canada and Australia, for over seven years, but the United States only approved the first such analyses last year (http://nnw.fm/jc2L0). As a result, no point of care tools are available to conduct true high-sensitivity testing, making the need for portable devices such as the MIDS product apparent. The technology is being developed to enable automated operation of the final device, suitable for use by minimally trained personnel, even in an ambulatory setting.
In July, the company posted quantitative testing results indicating that the MIDS technology had successfully detected a number of assay beads approximately four times lower than the maximum threshold required as suitable for a high-sensitivity troponin assay.
“The results of this second round of testing are quite extraordinary, as magnetic detection at this level for this application is unheard of,” Managing Director and Chief Scientific Officer Dr. Nasser Djennati stated in a news release (http://nnw.fm/DhGi7). “We can now move forward and apply the MIDS detection to established assay techniques used in conventional analyzers as we seek to deliver state-of-the-art laboratory standard, high sensitivity cardiac troponin testing at the Point of Care.”
Planning is now underway for the next key phase of development to test microfluidic detection on the revised electronics platform and to embody a high sensitivity assay on a test strip.
For more information, visit the company’s website at www.Zenosense.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Zenosense Inc. (ZENO) Stock Research Links
Scroll down for more posts ▼